---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-24-002570"
form_type: "8-K"
ticker: "CLDX"
cik: "0000744218"
company_name: "Celldex Therapeutics, Inc."
filed_at: "2024-05-06T23:59:59+00:00"
generated_at: "2026-06-02T22:36:02.065136+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Celldex reports Q1 net loss $32.8M; cash $823.8M; Phase 3 CSU studies planned summer 2024

## Summary
- Net loss of $32.8M ($0.56 per share) vs $29.4M ($0.62) in Q1 2023; revenue $0.2M.
- Cash, cash equivalents and marketable securities $823.8M, up from $423.6M due to $432.3M net public offering.
- Phase 3 CSU studies to initiate summer 2024; 52-week Phase 2 CSU data expected H2 2024.
- Phase 2 CIndU enrollment completed (196 patients); 12-week data due H2 2024.
- Atopic dermatitis selected as fifth indication; Phase 2 study to start by year-end 2024.

## SEC filing metadata
- accession: 0001171843-24-002570
- form_type: 8-K
- ticker: CLDX
- cik: 0000744218
- company_name: Celldex Therapeutics, Inc.
- filed_at: 2024-05-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/744218/000117184324002570/0001171843-24-002570-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/744218/000117184324002570/f8k_050624.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-24-002570
- JSON: https://secwatch.observer/filing/0001171843-24-002570.json
- Plain text: https://secwatch.observer/filing/0001171843-24-002570.txt

## Key facts
- Earnings Releases
  Celldex Therapeutics, Inc. reported financial results for first quarter ended March 31, 2024.
  - Period: first quarter ended March 31, 2024
  - Result: reported results
  source text: On May 6, 2024, Celldex Therapeutics, Inc. (the "Company") issued a press release announcing its financial results for the first quarter of 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/744218/000117184324002570/0001171843-24-002570-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.